Abstract 119P
Background
Waiting for the highest pCR is clinically relevant as this helps to choose the candidates for a watch–and–wait approach or local excision, identify the optimal operation timing, increase the chance of R0 resection, or improve disease–free survival and/or overall survival. Meanwhile, LR is a serious problem since it causes disabling symptoms, and successful salvage of pelvic recurrence is rarely possible. Therefore, this paper will investigate the impacts of dose fractionations of preoperative radiotherapy (RT) on pCR and LR for rectal cancer using three– or four–field conformal RT techniques.
Methods
The PubMed, Embase, and Web of Science databases (2000 to May 2018) were systematically searched for evidence. To evaluate the dose–response relationship, logistic response curves were fitted for pCR values, and the linear regression model was fitted for risk reduction of LR as a function of biologic effective dose (BED).
Results
Data from 8 comparative studies enrolling 14,869 patients were analyzed for pCR. Higher radiation doses were associated with increased pCR. If pCR curve was fitted using BED as a covariate, the dose required for 50% response (D50) ranged from 68·3 to 108·0 Gy. If BED was corrected with RT overall treatment time, The pCR curves of the similar treatment regimens in special patient cohorts interacted at identical D50, 50.7, 59.0, or 70.9 Gy. Regarding LR risk, 31 studies were identified and yielded 7,699 patients. Increasing RT doses was also associated with reduction in LR, and a linear dose–response effect of BED was seen on the risk reduction of LR. Each 1 Gy increase in BED would reduce LR by 1·36%, hence a hypothesis was proposed that a BED of approximately 73.5 Gy would need to achieve 100% LC.
Conclusions
Higher radiation doses were associated with increased pCR and LR reduction. In the future, by means of dose–response curves and the available pCR and LR values, we could perhaps obtain the dose gap to achieve 50% pCR response and 100% LC, and predict the amplitude of clinical benefits through limited RT dose escalation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract